McDougall I R
Division of Nuclear Medicine, Stanford Health Services, CA 94305, USA.
Nucl Med Commun. 1997 Jun;18(6):505-12. doi: 10.1097/00006231-199706000-00002.
Altogether, 147 scintiscans, completed 48-72 h after 74 MBq 131I, were compared with scintiscans obtained on average 7.8 days after therapeutic doses of 131I. The therapeutic doses ranged from 1100 to just over 7400 MBq. The reasons for the investigation were to determine (1) if the diagnostic dose interfered with uptake of the therapeutic dose and (2) how often more lesions, or greater extent of disease, was seen on the images using the larger therapy dose. The post-treatment scan showed less uptake in one region in 2 of the 147 patients (1.4%). The post-treatment scan showed more lesions in 12 patients (8%). In eight patients, the extent of disease, but not the stage of disease, was greater. In four patients, the stage of disease was increased, three due to lung uptake on the post-treatment scan which was not seen on the diagnostic scan and one due to uptake in lymph nodes on the post-treatment scan which was not present on the diagnostic scan. 74 MBq 131I seldom interferes with subsequent therapy and seldom underestimates the extent of thyroid cancer. It would appear to be an appropriate dose for diagnostic scintigraphy.
总共147次闪烁扫描在74MBq 131I注射后48 - 72小时完成，并与治疗剂量的131I注射后平均7.8天获得的闪烁扫描进行比较。治疗剂量范围为1100至略超过7400MBq。进行此项研究的目的是确定：（1）诊断剂量是否会干扰治疗剂量的摄取；（2）使用较大治疗剂量的图像上出现更多病灶或疾病范围更大的情况有多常见。治疗后扫描显示，147例患者中有2例（1.4%）在一个区域摄取减少。治疗后扫描显示12例患者（8%）出现更多病灶。8例患者疾病范围增大，但疾病分期未改变。4例患者疾病分期增加，3例是因为治疗后扫描显示肺部摄取而诊断扫描未显示，1例是因为治疗后扫描显示淋巴结摄取而诊断扫描未显示。74MBq 131I很少干扰后续治疗，很少低估甲状腺癌的范围。它似乎是诊断性闪烁扫描的合适剂量。
